What is rumination syndrome? Rumination syndrome, also called rumination disorder, causes recently eaten food to return to the mouth repeatedly, typically without the nausea or retching of vomiting. The pattern can become automatic; it is not proof that someone is deliberately making themselves sick. Assessment distinguishes it from reflux and other conditions. December 2025 clinical description.
Confidence: the symptom distinction and need for nutritional assessment are well-supported clinical concepts. Guidance recommends clinician-taught diaphragmatic breathing, with biofeedback when appropriate. A financially cleared universal cure, supplement or best medicine is not established by this review.
- Rumination means repeated post-meal regurgitation here; it is distinct from repetitive worried thinking.
- An automatic response can be addressed with therapy without blaming the person.
- The diagnosis rests on a careful history and appropriate evaluation, rather than one normal test.
- Nutrition, growth, dental effects and daily disruption deserve their own assessment.
- Breathing/biofeedback is an attributed clinical recommendation; small studies and incomplete funding chains limit independent outcome claims.
Table of contents
- Evidence summary
- Rumination disorder: regurgitation rather than forceful vomiting
- Abdominal pressure, the stomach valve and an automatic response
- Focused diagnosis and clinician-taught breathing or biofeedback
- Food intake, nutritional support and supplement claims
- What the human therapy studies can and cannot establish
- Swallowing difficulty, dehydration and emergency warnings
- Medicine review and the limits of reflux treatment
- Children, developmental needs and overlapping digestive symptoms
- A useful consultation record and follow-up plan
- Mechanistic hypotheses and the human-evidence boundary
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Post-meal regurgitation | Provider descriptions and dated expert review | Service/page financial gaps | Automatic symptoms require a clinical history, not blame. |
| Breathing/biofeedback | 2025 European clinical recommendation | Tier 3 connected authors; UEG industry income | Care role only; supporting trial finances not all cleared. |
| 2016 biofeedback trial | Small short adult placebo comparison | Developer-produced Tier 4 D; finance unclosed | Design only; independent efficacy excluded. |
| CBT expansion | Uncontrolled ten-adult proof-of-concept | Developer-produced Tier 4 D; family foundation | Design/feasibility only; independent efficacy excluded. |
| 2026 trial | Original indexed publication metadata | Full results/finance unreviewed | Existence disclosed; no superiority conclusion. |
| Supplements | No eligible replacement established in this review | Product/study chains not cleared | No brand, personal regimen or mechanism-to-benefit leap. |
Rumination disorder: regurgitation rather than forceful vomiting
Recognizable food can come back to the mouth and be swallowed again or spat out. The typical event feels relatively effortless compared with retching. Separate discomfort or reflux can occur as well, so “painless” is not a reason to dismiss a patient whose experience is more complicated. Typical pattern and accompanying symptoms.
Regurgitation is a symptom, not one diagnosis. Reflux can bring stomach contents into the throat; obstruction and other digestive problems can also produce relevant symptoms. The word regurgitation on its own does not identify the cause or justify borrowing someone else’s reflux treatment. Other causes of regurgitation.
This guide uses rumination to describe a digestive pattern. It does not mean someone must have an anxiety disorder, developmental disability or an eating disorder involving weight-control behaviour. Those concerns can be discussed where relevant, but should not replace assessment of the actual symptoms. Dated expert diagnostic context.
Abdominal pressure, the stomach valve and an automatic response
Abdominal-wall contraction can increase pressure while the valve between stomach and oesophagus relaxes, allowing recently swallowed food upward. Illness or stress may appear in the history; that association does not prove a cause in every person. Clinical mechanism review.
An involuntary pattern and a learnable competing response can coexist. Teaching asks the person to recognize the process and practice another response; it does not require admitting fault. A clinician should explain the purpose in language the patient understands, particularly when previous investigations or labels have left them feeling disbelieved. Age-appropriate explanation.
Focused diagnosis and clinician-taught breathing or biofeedback
Useful history includes the timing after eating, appearance of the returned food, nausea or retching, swallowing problems and any weight change. Selected oesophageal pressure/impedance testing after a meal may clarify uncertainty. A pressure trace is not a home measurement; its meaning depends on the symptoms and specialist interpretation. Selective investigation.
Endoscopy can investigate lining disease or another explanation; reflux monitoring assesses whether symptoms relate to acid or non-acid reflux. These tests answer different questions. A normal camera examination does not, by itself, diagnose an automatic post-meal response. Ask what uncertainty a proposed test is intended to resolve. Test-purpose context.
The 2025 UEG/ESNM consensus recommends diaphragmatic breathing, with or without biofeedback, as first-line care. Biofeedback uses measured signals to support learning rather than diagnosing every episode from appearance. This is an attributed clinical recommendation; its supporting trials have not all been financially cleared here. Current consensus care role.
The older expert review emphasizes explaining the diagnosis and teaching the technique. Having heard “breathe deeply” is not the same as receiving relevant instruction. Ask the treating professional to demonstrate, observe practice and explain when a reassessment is appropriate; this article does not substitute a timed exercise routine. Teaching and follow-up context.
Food intake, nutritional support and supplement claims
Symptoms can interfere with eating, friendships and school. Prolonged regurgitation can affect dental health and nutritional intake. Support should address daily disruption alongside episode frequency, including any food avoidance that makes intake harder. Adolescent daily-life concerns.
Adequate intake may require dietitian assessment, especially with weight loss or growth concerns. Severe malnutrition needs clinician-led planning, including the risks of restoring intake too quickly. A restrictive internet diet or a self-arranged feeding change is not a substitute for that assessment. Nutritional assessment.
No independently verified human evidence for a probiotic, enzyme, herbal mixture or nutrient replacing rumination therapy was established here. This is a limit of the reviewed evidence, not proof that every product has been tested. Nutritional replacement for a demonstrated deficiency has a different purpose from treating the regurgitation mechanism. Supplement decision context.
What the human therapy studies can and cannot establish
The original 2016 placebo-controlled biofeedback trial enrolled 24 adults at a referral centre. A small, short study can inform specialist care, but does not establish how every child, severely malnourished person or community patient will respond. Complete original finance and author interests were not retrieved, so this guide reports design rather than an independent success percentage. Original trial abstract.
A separate CBT proof-of-concept study offered treatment to ten adults; eight completed it. The study was uncontrolled and involved treatment developers. It explored feasibility and additional behavioural strategies, but cannot isolate comparative benefit against another credible treatment. Its named foundation funding and no-conflict declaration do not, on their own, close the foundation’s financial chain. Original design and disclosures.
A new trial was published online in February 2026 and in the July issue. The original indexed record confirms its existence, but full outcomes and finances were not available for this review. A recent date or a promising title cannot replace reading the study; no superior-treatment conclusion is drawn from that record. 2026 primary publication record.
A practical review can record meal disruption, intake, social participation and adverse effects alongside episode frequency. That record helps the next consultation, but improvement after several simultaneous changes cannot show which change caused it. Avoid turning a personal improvement or one clinic’s outcome into a guaranteed cure rate.
Swallowing difficulty, dehydration and emergency warnings
Difficulty swallowing, choking while eating, a wet voice after swallowing or feeling that food is stuck needs prompt clinical advice. These features should not be filed automatically under an existing rumination diagnosis. Progressive difficulty or inability to swallow safely requires reassessment of the cause and appropriate support. NHS: urgent swallowing assessment.
Reduced urine, persistent dizziness or inability to maintain fluids deserves urgent advice. Confusion, being difficult to wake or severe breathing difficulty can indicate an emergency. A familiar diagnosis does not make a new deterioration safe. Use the local urgent/emergency service and explain the established history without delaying help. Current dehydration warnings.
Blood or coffee-ground vomit, green vomit in an adult, yellow-green/green vomit in a child, sudden severe abdominal pain or headache, or a stiff neck with light sensitivity requires emergency assessment. Those are not a normal breathing-practice problem. Do not drive yourself to emergency care. Age-specific vomiting alarms.
Vomiting blood with faintness, confusion, black stool or feeling generally unwell also warrants emergency help. Tell staff about all medicines, including medicines that affect bleeding. An online guide cannot determine whether bleeding comes from irritation, a tear or another serious cause. Bleeding triage.
Medicine review and the limits of reflux treatment
Treatment depends on the cause of the symptom. Antacids or acid-suppressing medicines used for reflux do not automatically address every form of regurgitation. Conversely, an existing rumination diagnosis does not rule out another problem that deserves treatment. A clinician should distinguish the purpose of each proposed medicine. Cause-directed clinical context.
The European consensus discusses selected medication options when behavioural treatment is unavailable or insufficient and treating associated reflux when relevant. This is not a recommendation to self-start baclofen or an antidepressant. Suitability, adverse effects and monitoring require the prescribing team; commercially interested efficacy is excluded from the independent verdict. Selected clinical options.
Bring prescription and nonprescription medicines and supplement labels to review. A new symptom after a product change is useful information, rather than proof that the product caused it. Do not abruptly stop an essential prescription or replace prescribed care with a “gut support” combination. Disclosure and interaction precautions.
Children, developmental needs and overlapping digestive symptoms
Young people need explanations and practice adapted to their understanding and daily setting. Family support can help, while criticism or repeated demands to “keep food down” can make conversations harder. Ask how school meals, privacy and available support can fit the clinical plan. Supportive child/adolescent care context.
Early fullness, nausea and vomiting can also occur with gastroparesis, where stomach emptying is slow. Appropriate testing evaluates that possibility and alternatives. A diet or procedure discussed for gastroparesis should not be imported into rumination care merely because both symptoms occur after meals. Distinct delayed-emptying disorder.
Infant spit-up and a new forceful vomiting problem need age-specific assessment. Do not diagnose a baby from an adult description or thicken feeds on your own. The cause, growth and safety of feeding should be discussed with the pediatric team. Infant warning context.
A useful consultation record and follow-up plan
A symptom account can include meal timing, whether nausea or retching preceded the event, swallowing symptoms and what happened to the returned food. Record honestly rather than trying to make the history fit an online definition. If episodes vary, that variation is part of the information worth bringing. History-led assessment.
Ask which diagnosis is most likely, what alternatives remain and which findings would bring review forward. A test plan is easier to understand when each test has a stated purpose. Keep results together so another clinician can review what has already been assessed without assuming that every possibility has been excluded. Focused test purposes.
For therapy, practical questions include who will teach it, whether feedback is available, how difficulties will be addressed and how nutrition will be monitored. These are discussion prompts, not a required session count. Lack of early improvement should prompt review of teaching, diagnosis and care needs rather than blame or a more elaborate supplement stack.
For overlapping fullness or nausea, ask whether a dietitian assessment and a different investigation are appropriate. The current gastroparesis source illustrates why nutrition and diagnostic questions may need separate attention. Decisions should follow the actual assessment, rather than a fixed rule to avoid all solid food. Nutrition and evaluation roles.
Mechanistic hypotheses and the human-evidence boundary
Animal rumination and a laboratory pressure measurement are not evidence that an intervention improves this human condition. A plausible mechanism may help explain a treatment, but meaningful benefit needs human outcomes and harms in the relevant population. This guide does not count animal or in-vitro findings as clinical efficacy.
The independent verdict remains narrower than a treatment advertisement: appropriate assessment and clinician-taught therapy are care priorities; a universal cure, best drug or supplement replacement has not been independently established here. Funding gaps do not prove that a treatment fails, but prevent claiming that its benefit has passed a complete financial screen.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 22 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Provider education, narrative reviews, a society-funded consensus and outcome studies serve different roles. Financial routes are documented below without assigning a provider’s entire income to one page. Commercial efficacy is excluded from the independent verdict; missing trial and donor chains remain unclassified. Public hosting and a no-conflict declaration are not complete financial clearance.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| Cleveland Clinic: December 2025 rumination original | Own audited 2025 accounts show care payments, grants/gifts, investments and advisory activity. Advertising policy describes site support; page allocation, all contributors and trials unclosed. | United States; Cleveland, Ohio; provider information includes care/service promotion. | Tier 2 provider context, provisional. | C, provisional — actual 18 December 2025/25 February 2026 originals read. Clinical review favors accuracy; service/advertising incentives, simplification and unclosed page/trial finances remain. |
| Cleveland Clinic: February 2026 regurgitation original | Own audited 2025 accounts show care payments, grants/gifts, investments and advisory activity. Advertising policy describes site support; page allocation, all contributors and trials unclosed. | United States; Cleveland, Ohio; provider information includes care/service promotion. | Tier 2 provider context, provisional. | C, provisional — actual 18 December 2025/25 February 2026 originals read. Clinical review favors accuracy; service/advertising incentives, simplification and unclosed page/trial finances remain. |
| CUH: November 2022 rumination leaflet for ages 11+ | Own 2025–26 accounts disclose NHS/private care, research/training, donations and industry/charity partnerships. Leaflet allocation unknown. | United Kingdom; Cambridge University Hospitals, Hills Road, Cambridge. | Tier 2 provider context, provisional. | C, provisional — approved 23 November 2022; actual four-page original read, review deadline not supplied. Clinical psychology supports explanation; dated, simplified local advice and financial gaps remain. |
| Sasegbon et al: January 2022 clinical review | Original declares no specific grant or competing interests. Current institutional/author and supporting-trial finance unclosed. | United Kingdom; Manchester/Coventry authors; university-hosted original journal PDF. | Tier 2 historical context, provisional; independence unclassified. | C, provisional — actual relevant body/declarations read. Peer review aids scrutiny; narrative synthesis, age and financial gaps limit efficacy. |
| Halland, Pandolfino and Barba: 2018 expert review | No conflicts declared; project-funding statement not located. Current author/institutional and supporting-trial finance unclosed. | US/Spain: Mayo Rochester, Northwestern Chicago, Vall d’Hebron Barcelona; Portuguese-hosted original. | Tier 2 historical context, provisional. | C, provisional — actual original read. Expert appraisal aids explanation; no formal systematic review, current financial audit or drug ranking. |
| UEG/ESNM: January 2025 chronic nausea/vomiting consensus | Project funded by UEG. Own 2024 income chart and legal/financial page trace substantial industry/event income. Authors disclose pharmaceutical grants/fees and a pressure-flow patent; Spanish medical-writing support acknowledged. | European multinational panel; UEG incorporated/headquartered Vienna, Austria. | Tier 3 financially connected authors; corporate efficacy D/excluded. | C, provisional — actual relevant statements and declarations read. Graded Delphi methods aid scrutiny; many weak data, ESNM full finances, supplemental participants and original trial chains remain unclosed. |
| UEG: own legal, ownership and financial original | Membership, congress/education, journal and industry-support routes. Owns UEG GmbH in Vienna. Claims annual audit; full audited ledger not retrieved. | Austria; Wickenburggasse 1, Vienna; association register 570340662, GmbH FN 443867 x. | Tier 3 institutional financial self-disclosure. | B, provisional for actual stated routes/jurisdiction; management claims and incomplete donor/contract allocations do not prove clinical independence. |
| UEG: own 2024 funding-source chart | 2024 chart: sponsor/exhibition 52.78%, registration 35.47%; remaining educational, affiliation, journal and other income. Highest single-company contribution 5.10%. | Austria; UEG Vienna; own one-page public financial summary. | Tier 3 financial self-disclosure. | B, provisional — actual chart labels 2024 despite older PDF metadata. Not full audited accounts, named donor ledger or guideline allocation. |
| Barba et al: 2016 placebo-controlled biofeedback trial | Investigators developed the biofeedback technique. Full project finance/author interests unclosed; publisher full copy unavailable. | Spain; Vall d’Hebron Barcelona referral centre; complete backer chain unclosed. | Tier 4 developer-produced efficacy; D/excluded from independent benefit. | D for independent efficacy; C provisional for actual indexed abstract/design. Small, short, selected adult study; developer involvement and financial gaps limit causal independence. |
| Barba et al: February/July 2026 trial record | Full trial, sponsor allocation and complete author interests not retrieved; publication title/metadata alone supplies no financial clearance. | Spain/Israel affiliations; Barcelona and Jerusalem; metadata is hosted by US NLM. | Project independence unclassified. | C for actual indexed publication metadata only; no abstract/full outcome appraisal. New date is not proof of superiority or independence. |
| Murray et al: 2020/2021 CBT proof-of-concept study | Theodore Cross Family Charitable Foundation funding; authors declare no conflicts. Foundation’s full donors/ownership and complete investigator finances unclosed. | United States; Drexel Philadelphia, Massachusetts General Hospital/Harvard Boston; precise funder headquarters unverified. | Tier 4 developer-produced efficacy; D/excluded from independent benefit. | D for independent efficacy; C provisional for actual design/disclosures. Publisher abstract, funding and interests read. Uncontrolled small study and developer involvement prevent an independent causal comparison. |
| NHS: July 2026 gastroparesis original | Public national accounts; individual contributors, underlying trials and page allocation unclosed. | United Kingdom; national NHS England education. | Tier 1 institutional context, provisional. | B, provisional — 22 July 2026 original read. Care accountability supports diagnostic distinction; not independent clearance of its procedure/drug menu. |
| NIDDK: July 2020 GERD diagnosis original | NIH budget route; page-level reviewer and trial finances not supplied. Public hosting does not clear supporting studies. | United States; NIDDK, Bethesda, Maryland; federal education. | Tier 1 institution, provisional; page expert/trial chain unclassified. | C, provisional — actual July 2020 date/body read. Scientific review supports test-purpose context; older synthesis and financial gaps remain. |
| NHS: Dysphagia symptoms | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | C, provisional — public care accountability supports safety context; 2 May 2023; due 2 May 2026 passed. Simplification and incomplete page/expert/trial finance remain limits. |
| NHS: dehydration | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, 1 May 2026; due May 2029; not a trial-level financial audit. |
| NHS: December 2023 general vomiting original | National public accounts; page/trial finance unknown. | United Kingdom; national NHS England education. | Tier 1 institutional safety context, provisional. | B, provisional — actually reviewed 21 December 2023, due December 2026. Age-specific urgent triage and accountability favor safety; generic advice must not delay planned CVS rescue care. |
| NHS: vomiting blood | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, 18 August 2025; due August 2028; not a trial-level financial audit. |
| NCCIH: using supplements wisely | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
| Cleveland Clinic: original audited 2025/2024 accounts | Provider statutory report; externally audited by EY. Patient/payer revenue, advisory services, research grants, corporate/foundation/individual pledges and investments. | United States; Cleveland Clinic Health System, Cleveland, Ohio. | Tier 3 provider financial self-report with external audit. | B, provisional — issued 9 March 2026, complete 75-page original accessed and relevant notes read. Audit concerns the accounts, not this article or intervention trials. |
| Cleveland Clinic: advertising policy | Site accepts advertising/sponsor revenue; provider retains content/placement approval and states editorial separation. | United States; Cleveland, Ohio. | Tier 3 own commercial-policy disclosure. | B, provisional — policy itself read; January 2020 guidelines state they can change. Actual page advertiser amounts and compliance not independently audited. |
| Cleveland Clinic: editorial policy | Institutional writing and expert-review process; mixed provider funds above, no individual reviewer-payment ledger. | United States; Cleveland, Ohio. | Tier 3 own process disclosure. | B, provisional — actual policy describes professional writers and medical-expert review. Accuracy incentive is credible; an institutional perspective and unverified individual conflicts remain. |
| CUH: own 2025–2026 accounts | Provider accounts, notes 2.1–2.3: NHS care, private/overseas income, research, training and donations. Research section describes NIHR infrastructure and industry/charity partners. | United Kingdom; Cambridge NHS Foundation Trust. | Tier 3 financial self-report context. | B, provisional — statutory reporting and audit; aggregated service/research income, incomplete named donor and leaflet-payment chain. |
| NIDDK: original institutional budget | NIH/HHS federal budget record; institutional appropriations, not commercial trial clearance. | United States; NIDDK, Bethesda, Maryland. | Tier 3 public institutional financial record. | B, provisional — actual original budget route read earlier in this run; public accountability favors provenance. Page allocations and all experts/trials remain unknown. |
| NCCIH: own congressional-budget document | NIH/HHS federal congressional-budget documentation. Requested-year budgets and institutional priorities do not establish the finance of every cited supplement trial. | United States; NCCIH, Bethesda, Maryland. | Tier 1 public institution; budget self-report context. | B, provisional — traceable government-budget process; an older fiscal document and incomplete page/trial donor chain. |
| NHS England: national annual accounts | National NHS England statutory public financial report for 2024–2025. This is distinct from each hospital’s private, research or charitable income. | United Kingdom; national NHS England. | Tier 3 financial self-report context. | B, provisional — public statutory accountability and dated records; national totals do not identify individual page/expert payments. |
Frequently asked questions
Is rumination syndrome deliberate vomiting?
The usual pattern can be automatic and differs from nausea/retching-associated vomiting. The clinician should assess the actual history without assuming blame or a weight-control motive.
Does a normal endoscopy prove rumination?
No. Endoscopy examines particular structural/lining questions. History and, when appropriate, specialist physiological testing answer different questions.
Is diaphragmatic breathing a guaranteed cure?
No guaranteed outcome is established here. Guidance recommends clinician-taught practice, sometimes with biofeedback; response and nutrition need review.
Can I replace therapy with a probiotic or enzyme?
An independently verified replacement was not established. Review products and prescribed medicines with the clinical team, particularly when eating or hydration is affected.
Sources and funding notes
Originals checked 4 October 2026. Cleveland originals are December 2025 and February 2026; CUH leaflet November 2022. NHS dysphagia is May 2023 with its May 2026 review deadline passed; current safety originals corroborate urgent context. GERD test explanation is July 2020. Reviews are 2018 and January 2022, not later repository upload dates. UEG consensus January 2025; its own chart labels the financial period 2024 despite older PDF metadata. Full 2026 trial outcomes and complete trial/funder chains remain gaps. Source grades are provisional and role-specific.
- Cleveland Clinic: December 2025 rumination original — Automatic post-meal regurgitation and care assessment. No rarity/prognostic guarantee, numerical Rome IV checklist or unsupervised exercise adopted.
- Cleveland Clinic: February 2026 regurgitation original — Regurgitation is a symptom with several causes; no blanket attribution of Barrett’s/cancer risk to rumination or infant feeding recipe.
- CUH: November 2022 rumination leaflet for ages 11+ — Supportive child/adolescent explanation, dental and daily-life concerns; blanket “not an illness” wording and timed home exercise omitted.
- Sasegbon et al: January 2022 clinical review — 11 January 2022: physiology, selective tests and severe nutrition assessment; no outcome percentage.
- Halland, Pandolfino and Barba: 2018 expert review — 2018 publication, not 2023 upload: teaching/history; no dose or surgery shortcut.
- UEG/ESNM: January 2025 chronic nausea/vomiting consensus — First online 4 January 2025, author-name correction 10 January. Breathing/biofeedback first-line clinical recommendation, not independent replication or personal prescription.
- UEG: own legal, ownership and financial original — Funder’s own institutional routes; not an attribution to a particular recommendation or ESNM’s accounts.
- UEG: own 2024 funding-source chart — Institutional income mix only; sponsors of a particular trial are not inferred from totals.
- Barba et al: 2016 placebo-controlled biofeedback trial — 24 adults originally randomized; design only, no efficacy percentage, equivalence or universal cure.
- Barba et al: February/July 2026 trial record — 13 February 2026 online/July issue; existence disclosed, results not inferred from title or a separate CME disclosure.
- Murray et al: 2020/2021 CBT proof-of-concept study — 11 November 2020 online, October 2021 issue: ten adults, eight completers, uncontrolled; design/feasibility context only, outcomes excluded.
- NHS: July 2026 gastroparesis original — Delayed emptying, nausea and selective testing only; no gastroparesis diet/procedure transplanted into rumination care.
- NIDDK: July 2020 GERD diagnosis original — Endoscopy and reflux-monitoring purposes, not a rumination diagnostic rule, personal preparation or efficacy claim.
- NHS: Dysphagia symptoms — Actual 2 May 2023, due 2 May 2026 passed: urgent difficulty swallowing, choking and food-sticking assessment; no automatic reflux/rumination attribution.
- NHS: dehydration — Actual 1 May 2026: reduced urine, urgent dehydration and emergency deterioration; no universal fluid target.
- NHS: December 2023 general vomiting original — Actual 21 December 2023, due December 2026: blood/green vomit, severe sudden pain and neurological emergency signs; age-specific care.
- NHS: vomiting blood — Actual 18 August 2025: bleeding with faintness/confusion/black stool or illness requires emergency assessment.
- NCCIH: using supplements wisely — Labels, medicine disclosure and interactions; no rumination-specific efficacy verdict.
- Cleveland Clinic: original audited 2025/2024 accounts — Printed pp9–12, 18–20, 22 and 32 identify routes; no claim of complete June 2026 interim or page-specific independence.
- Cleveland Clinic: advertising policy — Ad-finance route and stated editorial safeguards, not disease efficacy.
- Cleveland Clinic: editorial policy — Process context; not a guarantee that every clinical sentence is accurate or financially independent.
- CUH: own 2025–2026 accounts — Actual provider-level financial provenance; not independent clinical-outcome evidence.
- NIDDK: original institutional budget — Institutional financing only; the GI series explicitly thanks an outside expert with separately disclosed commercial ties.
- NCCIH: own congressional-budget document — Verify federal institutional funding, not disease-specific supplement benefit.
- NHS England: national annual accounts — Finance provenance for national patient education only.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
